The reproductive potential of vitrifiedwarmed euploid embryos declines following repeated uterine transfers
Metadatos
Mostrar el registro completo del ítemAutor
Almohammadi, A.; Choucair, F.; El Taha, L.; Burjaq, H.; Albader, M.; Bueno Cavanillas, Aurora; Awwad, Johnny T.Editorial
BioMed Central Ltd
Materia
Recurrent implantation failure Preimplantation genetic testing for aneuploidy Euploid blastocyst rate
Fecha
2024-02-13Referencia bibliográfica
Almohammadi, A., Choucair, F., El Taha, L. et al. The reproductive potential of vitrified-warmed euploid embryos declines following repeated uterine transfers. Reprod Biol Endocrinol 22, 23 (2024). https://doi.org/10.1186/s12958-024-01192-z
Resumen
Background Recurrent implantation failure (RIF) represents a vague clinical condition with an unclear diagnostic
challenge that lacks solid scientific underpinning. Although euploid embryos have demonstrated consistent
implantation capabilities across various age groups, a unanimous agreement regarding the advantages of
preimplantation genetic testing for aneuploidy (PGT-A) in managing RIF is absent. The ongoing discussion about
whether chromosomal aneuploidy in embryos significantly contributes to recurrent implantation failure remains
unsettled. Despite active discussions in recent times, a universally accepted characterization of recurrent implantation
failure remains elusive. We aimed in this study to measure the reproductive performance of vitrified-warmed euploid
embryos transferred to the uterus in successive cycles.
Methods This observational cohort study included women (n = 387) with an anatomically normal uterus who
underwent oocyte retrieval for PGT-A treatment with at least one biopsied blastocyst, between January 2017 and
December 2021 at a university-affiliated public fertility center. The procedures involved in this study included ICSI,
blastocyst culture, trophectoderm biopsy and comprehensive 24-chromosome analysis of preimplantation embryos
using Next Generation Sequencing (NGS). Women, who failed a vitrified-warmed euploid embryo transfer, had
successive blastocyst transfer cycles (FET) for a total of three using remaining cryopreserved euploid blastocysts from
the same oocyte retrieval cycle. The primary endpoints were sustained implantation rate (SIR) and live birth rate (LBR)
per vitrified-warmed single euploid embryo. The secondary endpoints were mean euploidy rate (m-ER) per cohort of
biopsied blastocysts from each patient, as well as pregnancy and miscarriage rates.
Results The mean age of the patient population was 33.4 years (95% CI 32.8–33.9). A total of 1,641 embryos derived
from the first oocyte retrieval cycle were biopsied and screened. We found no associations between the m-ER and
the number of previous failed IVF cycles among different ranges of maternal age at oocyte retrieval (P = 0.45). Pairwise
comparisons showed a significant decrease in the sustained implantation rate (44.7% vs. 30%; P = 0.01) and the
livebirth rate per single euploid blastocyst (37.1% vs. 25%; P = 0.02) between the 1st and 3rd FET. The cumulative SIR
and LBR after up to three successive single embryo transfers were 77.1% and 68.8%, respectively. We found that the live birth rate of the first vitrified-warmed euploid blastocyst transferred decreased significantly with the increasing
number of previously failed IVF attempts by categories (45.3% vs. 35.8% vs. 27.6%; P = 0.04). A comparable decrease in
sustained implantation rate was also observed but did not reach statistical significance (50% vs. 44.2 vs. 37.9%; P = NS).
Using a logistic regression model, we confirmed the presence of a negative association between the number of
previous IVF failed attempts and the live birth rate per embryo transfer cycle (OR = 0.76; 95% CI 0.62–0.94; P = 0.01).
Conclusions These findings are vital for enhancing patient counseling and refining management strategies
for individuals facing recurrent implantation failure. By tailoring interventions based on age and ovarian reserve,
healthcare professionals can offer more personalized guidance, potentially improving the overall success rates and
patient experiences in fertility treatments.